A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction

Ryo Watanabe, Jun Ichi Suzuki, Kouji Wakayama, Yasuhiro Maejima, Munehisa Shimamura, Hiroshi Koriyama, Hironori Nakagami, Hidetoshi Kumagai, Yuichi Ikeda, Hiroshi Akazawa, Ryuichi Morishita, Issei Komuro, Mitsuaki Isobe

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

A peptide vaccine targeting angiotensin II (Ang II) was recently developed as a novel treatment for hypertension to resolve the problem of noncompliance with pharmacotherapy. Ang II plays a crucial role in the pathogenesis of cardiac remodeling after myocardial infarction (MI), which causes heart failure. In the present study, we examined whether the Ang II vaccine is effective in preventing heart failure. The injection of the Ang II vaccine in a rat model of MI attenuated cardiac dysfunction in association with an elevation in the serum anti-Ang II antibody titer. Furthermore, any detrimental effects of the Ang II vaccine were not observed in the rats that underwent sham operations. Treatment with immunized serum from Ang II vaccine-injected rats significantly suppressed post-MI cardiac dysfunction in MI rats and Ang II-induced remodeling-associated signaling in cardiac fibroblasts. Thus, our present study demonstrates that the Ang II vaccine may provide a promising novel therapeutic strategy for preventing heart failure.

Original languageEnglish (US)
Article number43920
JournalScientific Reports
Volume7
DOIs
Publication statusPublished - Mar 7 2017

    Fingerprint

ASJC Scopus subject areas

  • General

Cite this

Watanabe, R., Suzuki, J. I., Wakayama, K., Maejima, Y., Shimamura, M., Koriyama, H., ... Isobe, M. (2017). A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Scientific Reports, 7, [43920]. https://doi.org/10.1038/srep43920